Congress Passes Legislation Codifying FDA’s “Active Moiety” Approach to Exclusivity Determinations

Published date26 April 2021
Subject MatterFDA,FDCA,Prescription Drugs,New Legislation,FDA Approval,Exclusivity,Pharmaceutical Industry
AuthorAndrew Kim,Brian Burgess,Alexander Varond
Law FirmGoodwin

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT